Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Interest & Investment Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Interest & Investment Income for 6 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 40.6% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.2 million, a 14.92% decrease, with the full-year FY2024 number at $27.0 million, up 121.52% from a year prior.
  • Interest & Investment Income was $4.3 million for Q3 2025 at 4D Molecular Therapeutics, down from $4.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.5 million in Q2 2024 to a low of -$312000.0 in Q4 2021.
  • A 5-year average of $3.0 million and a median of $2.5 million in 2023 define the central range for Interest & Investment Income.
  • Biggest YoY gain for Interest & Investment Income was 10775.0% in 2021; the steepest drop was 7900.0% in 2021.
  • 4D Molecular Therapeutics' Interest & Investment Income stood at -$312000.0 in 2021, then surged by 528.85% to $1.3 million in 2022, then surged by 227.35% to $4.4 million in 2023, then soared by 47.65% to $6.5 million in 2024, then tumbled by 33.04% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Interest & Investment Income are $4.3 million (Q3 2025), $4.9 million (Q2 2025), and $5.6 million (Q1 2025).